Hesham Mohamed
Ain Shams University(EG)St. Joseph's Hospital and Medical Center(US)Misr University for Science and Technology(EG)Regeneron (United States)(US)Zagazig University(EG)Egyptian Society of Chest Diseases and Tuberculosis(EG)Progenics Pharmaceuticals (United States)(US)Mayo Clinic in Arizona(US)Abderrahmane Mami Hospital(TN)Fayoum University(EG)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Transplantation: Methods and Outcomes, Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)(2013)390 cited
- → Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study(2014)195 cited
- → Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034(2016)180 cited
- → Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial(2022)112 cited
- → Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma(2024)69 cited
- → Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial